D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: A metaregression analysis

Psychopharmacology

Volumn 231, Issue 18, 2014, Pages 3765-3770

  Ducasse, Deborah ^a   Boyer, Laurent ^b   Michel, Pierre ^b   Loundou, Anderson ^b   Macgregor, Alexandra ^a   Micoulaud Franchi, Jean Arthur ^d   Courtet, Philippe ^a   Abbar, Mocrane ^e   Leboyer, Marion ^c   Fond, Guillaume ^a  

^a UNIV MONTPELLIER   (France)

^b TIMONE HOSPITAL   (France)

^c UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^d HÔPITAL SAINTE MARGUERITE   (France)

^e DEPARTMENT OF NEUROLOGY   (France)

Author keywords

Antipsychotic; D2; D3; Dopamine receptor binding affinity; Obsessive compulsive disorder

Indexed keywords

ARIPIPRAZOLE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN RECEPTOR;

ADD ON THERAPY; ARTICLE; BINDING AFFINITY; DRUG EFFICACY; DRUG RECEPTOR BINDING; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; OBSESSIVE COMPULSIVE DISORDER; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR AFFINITY; METABOLISM; OBSESSIVE-COMPULSIVE DISORDER;

ANTIPSYCHOTIC AGENTS; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, SEROTONIN;

EID: 84906934880     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3516-3     Document Type: Article

References (31)

1. AFSSAPS (2006) Good use of antidepressants in the treatment of depressive and anxiety disorders in adults. http://ansm.sante.fr/var/ansm-site/storage/ original/application/9698d423c76ea69ed0a2678ff7a2b2b3.pdf. Accessed 5 Oct 2013
2. APA APA (2013) Diagnostic and statistical manual of mental disorders: fifth edition DSM5.
3. Atmaca M, Kuloglu M, Tezcan E, Gecici O (2002) Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol 17:115-119 (Pubitemid 34442192)
4. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF (2006) A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 11:622-632 (Pubitemid 43989810)
5. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR (2009) Introduction to meta-analysis. Wiley, Chichester, UK
6. Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S (2004) Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry 65:565-568
7. Carey PD, Vythilingum B, Seedat S,Muller JE, van Ameringen M, Stein DJ (2005) Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. BMC Psychiatr 5:5
8. Collins PY, Insel TR, Chockalingam A, Daar A, Maddox YT (2013) Grand challenges in global mental health: integration in research, policy, and practice. PLoS Med 10:e1001434
9. Denys D, de Geus F, van Megen HJ, Westenberg HG (2004a) A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 65:1040-1048
10. Denys D, de Vries F, Cath D, Figee M, Vulink N, Veltman DJ, van der Doef TF, Boellaard R, Westenberg H, van Balkom A, Lammertsma AA, van Berckel BN (2013) Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder. Eur Neuropsychopharmacol : The Journal of the European College of Neuropsychopharmacology 23:1423-1431
11. Denys D, Van Nieuwerburgh F, Deforce D, Westenberg H (2006) Association between the dopamine D2 receptor TaqI A2 allele and low activity COMT allele with obsessive-compulsive disorder in males. Eur Neuropsychopharmacol: The Journal of the European College of Neuropsychopharmacology 16:446-450 (Pubitemid 43975350)
12. Denys D, Zohar J, Westenberg HG (2004b) The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry 65(Suppl 14):11-17
13. Diniz JB, Shavitt RG, Fossaluza V, Koran L, Pereira CA, Miguel EC (2011) A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder. J Clin Psychopharmacol 31(6):763-8. doi:10.1097/JCP.0b013e3182367aee
14. Dold M, Aigner M, Lanzenberger R, Kasper S (2013) Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol/Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum 16:557-574
15. Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L (2005) Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol: The Journal of the European College of Neuropsychopharmacology 15:69-74 (Pubitemid 39574401)
16. Fineberg NA, Gale TM (2005) Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol/Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum 8:107-129
17. Hollander E, Kaplan A, Stahl SM (2003) A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder. World J Biol Psychiatry: The Official Journal of the World Federation of Societies of Biological Psychiatry 4:30-34
18. KarayiorgouM, Sobin C, BlundellML, Galke BL,Malinova L,Goldberg P, Ott J, Gogos JA (1999) Family-based association studies support a sexually dimorphic effect of COMT and MAOA on genetic susceptibility to obsessive-compulsive disorder. Biol Psychiatry 45:1178-1189 (Pubitemid 29236559)
19. Kordon A, Wahl K, Koch N, Zurowski B, Anlauf M, Vielhaber K, Kahl KG, Broocks A, Voderholzer U, Hohagen F (2008) Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol 28:550-554
20. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH (2000) A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 57:794-801 (Pubitemid 30650116)
21. McDougle CJ, GoodmanWK, Leckman JF, Lee NC, Heninger GR, Price LH (1994) Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 51:302-308 (Pubitemid 24127303)
22. Metin O, Yazici K, Tot S, Yazici AE (2003) Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial. Hum Psychopharmacol 18:463-467 (Pubitemid 37038343)
23. Muscatello MR, Bruno A, Pandolfo G, Mico U, Scimeca G, Romeo VM, Santoro V, Settineri S, Spina E, Zoccali RA (2011) Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol 31:174-179
24. Perani D, Garibotto V, Gorini A, Moresco RM, Henin M, Panzacchi A, Matarrese M, Carpinelli A, Bellodi L, Fazio F (2008) In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder. NeuroImage 42:306-314
25. Pirot S (1998) TOC et sérotonine: données contradictoires actuelles et perspectives thérapeutiques. Neuropsychiatrie: Tendances et Débats 3:39-43
26. Richtand NM, Welge JA, Logue AD, Keck PE Jr, Strakowski SM, McNamara RK (2007) Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology: Official publication of the American College of Neuropsychopharmacology 32:1715-1726
27. Roth BL, Lopez E, Beischel S, Westkaemper RB, Evans JM (2004) Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery. Pharmacol Ther 102:99-110 (Pubitemid 38681010)
28. Sayyah M, Sayyah M, Boostani H, Ghaffari SM, Hoseini A (2012) Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial). Depress Anxiety 29:850-854
29. Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MC, Blier P, Goodman WK (2004) A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry 55:553-555 (Pubitemid 38338545)
30. Somers JM, Goldner EM, Waraich P, Hsu L (2006) Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. Can J Psychiatry 51:100-113
31. Ugedo L, Grenhoff J, Svensson TH (1989) Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 98:45-50 (Pubitemid 19117342)